69 results about "Virus suspension" patented technology

The invention discloses a method for producing animal rabies viruses and animal rabies vaccines on a large scale. By using a bioreactor, the animal rabies viruses and the animal rabies vaccines are produced by a cell micro-carrier suspension culturing system on a large scale by the following steps of: inoculating cells for preparing the vaccine into a carrier tank containing culture solution and micro-carriers to attach the cells to the micro-carriers; growing the cells on the micro-carriers until the concentration of culture solution is 5 to 20 times the inoculation concentration under a proper culturing environment; preparing virus suspension from the rabies virus to adsorb the virus suspension to the cells; replacing cell maintenance culture solution to culture the virus under the proper culturing environment; continuously culturing for 3 to 5 days and harvesting the virus solution for the first time, wherein the solution replacement ratio is 50 percent by using a semi-continuous process; continuously culturing for 9 to 11 days and harvesting and replacing the solution once every 24 hours; and mixing the harvested virus solution and the virus solution of the bioreactor, repeatedly performing freeze-thawing twice at the constant temperature of -20 DEG C, inactivating, purifying and adding adjuvants to prepare the rabies vaccine. The method has the advantages of large production scale, high single-batch yield and relatively low production cost.

The present invention provides for a novel oil-in-water (O / W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. In one embodiment, the present invention provides for an injectable oil-in-water (O / W) emulsion comprising:(1) an aqueous solution containing an immunogen, said immunogen selected from the group comprising an inactivated Mycoplasma hyopneumoniae bacterium, an inactivated d porcine circovirus type 2 (PCV-2) virus or combinations thereof;(2) a mineral oil;(3) a non-ionic lipophilic surfactant; and(4) a non-ionic hydrophilic surfactant having a low HLB value which comprises ethoxylated fatty acid diesters of sorbitan (generally having HLB value between 11 and 13).